A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.

Trial Profile

A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the symptomatic treatment of Adults with Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms REPOSE
  • Sponsors Allergan
  • Most Recent Events

    • 29 Nov 2017 According to an Allergan media release, data from the study will be presented at the 11th European Headache Federation (EHF) Congress 2017.
    • 10 Sep 2017 Results assessing long term use of Onabotulinumtoxin A (BOTOX) as prescribed by the physician for headache prophylaxis in adults with chronic migraine, were presented at the 2017 International Headache Society.
    • 06 Sep 2017 According to an Allergan media release, data from the study will be presented at the upcoming 18th Congress of the International Headache Society (IHC2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top